455
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019

ORCID Icon, , ORCID Icon, , , ORCID Icon, , & show all
Article: 2360568 | Received 26 Feb 2024, Accepted 20 May 2024, Published online: 09 Jun 2024

References

  • Cho A, Jantschitsch C, Knobler R. Extracorporeal photopheresis-An overview. Front Med (Lausanne). 2018;5:1. doi:10.3389/fmed.2018.00236.
  • Bagherani N, Smoller BR. An overview of cutaneous T cell lymphomas. F1000Res. 2016;5:5. doi:10.12688/f1000research.8829.1.
  • Dobos G, Pohrt A, Ram-Wolff C, et al. Epidemiology of cutaneous T-cell lymphomas: a systematic review and meta-analysis of 16,953 patients. Cancers (Basel). 2020;12(10):2921. doi:10.3390/cancers12102921.
  • Ottevanger R, van Beugen S, Evers AWM, et al. Itch in patients with cutaneous T-cell lymphoma as a quality of life indicator. JAAD Int. 2022;9:57–6. doi:10.1016/j.jdin.2022.07.007.
  • Ottevanger R, van Beugen S, Evers AWM, et al. Quality of life in patients with mycosis fungoides and sézary syndrome: a systematic review of the literature. J Eur Acad Dermatol Venereol. 2021;35(12):2377–2387. doi:10.1111/jdv.17570.
  • Williams K, Gibson A, McNamara L, et al. Health state utilities associated with caring for an individual with cutaneous T-cell lymphoma (CTCL). J Med Econ. 2020;23(10):1142–1150. doi:10.1080/13696998.2020.1793764.
  • Knobler R, Arenberger P, Arun A, et al. European dermatology forum - updated guidelines on the use of extracorporeal photopheresis 2020 - part 1. J Eur Acad Dermatol Venereol. 2020;34(12):2693–2716. doi:10.1111/jdv.16890.
  • Goussetis E, Varela I, Tsirigotis P. Update on the mechanism of action and on clinical efficacy of extracorporeal photopheresis in the treatment of acute and chronic graft versus host disease in children. Transfus Apher Sci. 2012;46(2):203–209. doi:10.1016/j.transci.2011.10.017.
  • Mallinckrodt. Prescribing information uvadex. 2023. Accessed July 26, 2023. https://patient.therakos.com/globalassets/files/prescribing-information-uvadex.pdf
  • National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: primary cutaneous lymphomas version 2. 2021. Accessed December 13, 2021, https://www.nccn.org/professionals/physician_gls/pdf/primary_cutaneous.pdf.
  • Zic JA. Extracorporeal photopheresis in the treatment of mycosis fungoides and sézary syndrome. Dermatol Clin. 2015;33(4):765–776. doi:10.1016/j.det.2015.05.011.
  • Yalniz FF, Murad MH, Lee SJ, et al. Steroid refractory chronic graft-versus-host disease: cost-effectiveness analysis. Biol Blood Marrow Transplant. 2018;24(9):1920–1927. doi:10.1016/j.bbmt.2018.03.008.
  • Hanel W, Briski R, Ross CW, et al. A retrospective comparative outcome analysis following systemic therapy in mycosis fungoides and sezary syndrome. Am J Hematol. 2016;91(12):E491–e495. doi:10.1002/ajh.24564.
  • Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and sézary syndrome: a consensus statement of the international society for cutaneous lymphomas, the United States cutaneous lymphoma consortium, and the cutaneous lymphoma task force of the european organisation for research and treatment of cancer. J Clin Oncol. 2011;29(18):2598–2607. doi:10.1200/jco.2010.32.0630.
  • Zic JA, Stricklin GP, Greer JP, et al. Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. J Am Acad Dermatol. 1996;35(6):935–945. doi:10.1016/s0190-9622(96)90118-8.
  • Alfred A, Taylor PC, Dignan F, et al. The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK photopheresis society. Br J Haematol. 2017;177(2):287–310. doi:10.1111/bjh.14537.